MicroRNAs and SARS-CoV-2 life cycle, pathogenesis, and mutations: biomarkers or therapeutic agents?

References

• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733.
   Web of Science ®Google Scholar
• Matta S, Chopra K, Arora V. Morbidity and mortality trends of Covid 19 in top 10 countries. Indian J Tubercul. 2020;67(4):167–172.
   Google Scholar
• Of the International CSG. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536.
   PubMed Web of Science ®Google Scholar
• Yang Y, Xiao Z, Ye K, et al. SARS-CoV-2: characteristics and current advances in research. Virol J. 2020;17:1–17.
   PubMed Web of Science ®Google Scholar
• Reddm WD, Zhou JC, Hathorn KE, et al. Prevalence and characteristics of gastrointestinal symptoms in patients with severe acute respiratory syndrome Coronavirus 2 infection in the United States: A multicenter cohort study. Gastroenterology. 2020;159(2):765–767.
   Web of Science ®Google Scholar
• Costanzo M, De Giglio MAR, Roviello GN. SARS-CoV-2: recent reports on antiviral therapies based on lopinavir/ritonavir, darunavir/ umifenovir,hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus. Current medicinal chemistry; 2020.
   Google Scholar
• McKee DL, Sternberg A, Stange U, et al. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res. 2020;157:104859.
   PubMed Web of Science ®Google Scholar
• Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5:1–14.
   PubMed Web of Science ®Google Scholar
• Bernier A, Sagan SM. The diverse roles of microRNAs at the host–virus interface. Viruses. 2018;10:440.
   Web of Science ®Google Scholar
• Leon-Icaza SA, Zeng M, Rosas-Taraco AG. microRNAs in viral acute respiratory infections: immune regulation, biomarkers, therapy, and vaccines. ExRNA. 2019;1(1):1–7.
   PubMedGoogle Scholar
• Lu TX, Rothenberg ME. MicroRNA. J Allergy Clin Immunol. 2018;141(4):1202–1207.
   PubMed Web of Science ®Google Scholar
• O’Brien J, Hayder H, Zayed Y, et al. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018;9:402.
   PubMed Web of Science ®Google Scholar
• Shi Y, Jin Y. MicroRNA in cell differentiation and development. Sci China Ser C Life Sci. 2009;52:205–211.
   PubMedGoogle Scholar
• Rodrigues D, Monteiro VVS, Navegantes-Lima KC, et al. MicroRNAs in cell cycle progression and proliferation: molecular mechanisms and pathways. Non-Cod RNA Invest. 2018;2:28.
   Google Scholar
• Bruscella P, Bottini S, Baudesson C, et al. Viruses and miRNAs: more friends than foes. Front Microbiol. 2017;8:824.
   PubMed Web of Science ®Google Scholar
• Grundhoff A, Sullivan CS. Virus-encoded microRNAs. Virology. 2011;411:325–343.
   PubMed Web of Science ®Google Scholar
• Mallick B, Ghosh Z, Chakrabarti J. MicroRNome analysis unravels the molecular basis of SARS infection in bronchoalveolar stem cells. PloS One. 2009;4:e7837.
   PubMed Web of Science ®Google Scholar
• Hasan MM, Akter R, Ullah M, et al. A computational approach for predicting role of human microRNAs in MERS-CoV genome. Adv Bioinformatics. 2014;2014.
   Google Scholar
• Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proceedings of the National Academy of Sciences; Saint Paul, MN; 2020;117:11727–11734.
   Google Scholar
• V’kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: implications for SARS-CoV-2. Nature Rev Microbiol. 2020;1–16.
   PubMed Web of Science ®Google Scholar
• Poduri R, Joshi G, Jagadeesh G. Drugs targeting various stages of the SARS-CoV-2 life cycle: exploring promising drugs for the treatment of Covid-19. Cell Signal. 2020;74:109721.
   PubMed Web of Science ®Google Scholar
• Kim D, Lee J-Y, Yang J-S, et al. The architecture of SARS-CoV-2 transcriptome. Cell. 2020;181(4):914–921.
   Google Scholar
• Khan M-A-A-K, Sany MRU, Islam MS, et al. Epigenetic regulator miRNA pattern differences among SARS-CoV, SARS-CoV-2 and SARS-CoV-2 world-wide isolates delineated the mystery behind the epic pathogenicity and distinct clinical characteristics of pandemic COVID-19. bioRxiv. 2020;11:765.
   Google Scholar
• Demirci MDS, Adan A. Computational analysis of microRNA-mediated interactions in SARS-CoV-2 infection. PeerJ. 2020;8:e9369.
   PubMed Web of Science ®Google Scholar
• Rad AH, McLellan AD. Implications of SARS-CoV-2 mutations for genomic RNA structure and host microRNA targeting. bioRxiv. 2020;21(13):4807.
   Google Scholar
• Liu Z, Wang J, Xu Y, et al. Implications of the virus-encoded miRNA and host miRNA in the pathogenicity of SARS-CoV-2. arXiv. 2020;arXiv preprint arXiv:200404874. 2020.
   Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.
   Web of Science ®Google Scholar
• Arisan ED, Dart A, Grant GH, et al. The prediction of miRNAs in SARS-CoV-2 genomes: hsa-miR databases Identify 7 key miRs linked to host responses and virus pathogenicity-related KEGG pathways significant for comorbidities. Viruses. 2020;12:614.
   Web of Science ®Google Scholar
• Matarese A, Gambardella J, Sardu C, et al. miR-98 regulates TMPRSS2 expression in human endothelial cells: key implications for COVID-19. Biomedicines. 2020;8(11):462.
   PubMed Web of Science ®Google Scholar
• Nersisyan S, Shkurnikov M, Turchinovich A, et al. Integrative analysis of miRNA and mRNA sequencing data reveals potential regulatory mechanisms of ACE2 and TMPRSS2. Plos One. 2020;15:e0235987.
   PubMed Web of Science ®Google Scholar
• Sardar R, Satish D, Birla S, et al. Comparative analyses of SAR-CoV2 genomes from different geographical locations and other coronavirus family genomes reveals unique features potentially consequential to host-virus interaction and pathogenesis. bioRxiv. 2020.
   Google Scholar
• Haddad H, Al-Zyoud W. miRNA target prediction might explain the reduced transmission of SARS-CoV-2 in Jordan, Middle East. Noncoding RNA Res. 2020;5:135–143.
   PubMed Web of Science ®Google Scholar
• Sardar R, Satish D, Birla S, et al. Integrative analyses of SARS-CoV-2 genomes from different geographical locations reveal unique features potentially consequential to host-virus interaction, pathogenesis and clues for novel therapies. Heliyon. 2020;6:e04658.
   PubMed Web of Science ®Google Scholar
• Tang H, Lu X, Qie S, et al. Thoughts on detecting tissue distribution of potential COVID-19 receptors. Future Virol. 2020;15:489–496.
   Web of Science ®Google Scholar
• Bahrami A, Bakherad M Comparative genomics identifies key genes and miRNAs that may be used as a strategy to control and treatment of COVID-19; 2020.
   Google Scholar
• Mukhopadhyay D, Mussa BM. Identification of novel hypothalamic microRNAs as promising therapeutics for SARS-CoV-2 by regulating ACE2 and TMPRSS2 expression: an in silico analysis. Brain Sci. 2020;10:666.
   Web of Science ®Google Scholar
• Lu D, Chatterjee S, Xiao K, et al. MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes. J Mol Cell Cardiol. 2020;148:46–49.
   Web of Science ®Google Scholar
• Shao M, Li X, Liu F, et al. Acute kidney injury is associated with severe infection and fatality in patients with COVID-19: a systematic review and meta-analysis of 40 studies and 25,278 patients. Pharmacol Res. 2020;;161:105107.
   Web of Science ®Google Scholar
• Widiasta A, Sribudiani Y, Nugrahapraja H, et al. Potential role of ACE2-related microRNAs in COVID-19-associated nephropathy. Noncoding RNA Res. 2020;5:153–166.
   PubMed Web of Science ®Google Scholar
• Walsh D, Mathews MB, Mohr I. Tinkering with translation: protein synthesis in virus-infected cells. Cold Spring Harb Perspect Biol. 2013;5:a012351.
   PubMed Web of Science ®Google Scholar
• Chen L, Zhong L Genomics functional analysis and drug screening of SARS-CoV-2. Genes & Diseases; 2020.
   Google Scholar
• Cullen BR. Viruses and microRNAs: rISCy interactions with serious consequences. Genes Dev. 2011;25:1881–1894.
   PubMed Web of Science ®Google Scholar
• Rakhmetullina A, Ivashchenko A, Akimniyazova A, et al. The miRNA complexes against coronaviruses COVID-19, SARS-CoV, And MERS-CoV; 2020.
   Google Scholar
• Ivashchenko A, Rakhmetullina A, Aisina D How miRNAs can protect humans from coronaviruses COVID-19, SARS-CoV, and MERS-CoV; 2020.
   Google Scholar
• Zhang T, Cheng T, Wei L, et al. Efficient inhibition of HIV-1 replication by an artificial polycistronic miRNA construct. Virol J. 2012;9:118.
   PubMed Web of Science ®Google Scholar
• Gao J, Xiao S, Xiao Y, et al. MYH9 is an essential factor for porcine reproductive and respiratory syndrome virus infection. Sci Rep. 2016;6:1–13.
   PubMed Web of Science ®Google Scholar
• Orozco-García E, Trujillo-Correa A, Gallego-Gómez JC Cell biology of virus infection. The Role of Cytoskeletal Dynamics Integrity in the Effectiveness of Dengue Virus Infection. Cell Biology-New Insights: IntechOpen; 2016.
   Google Scholar
• Spear M, Wu Y. Viral exploitation of actin: force-generation and scaffolding functions in viral infection. Virol Sin. 2014;29:139–147.
   PubMedGoogle Scholar
• Cong Y, Ulasli M, Schepers H, et al. Nucleocapsid protein recruitment to replication-transcription complexes plays a crucial role in coronaviral life cycle. J Virol. 2020;94(4).
   Web of Science ®Google Scholar
• Yoshimoto FK. The proteins of severe acute respiratory syndrome coronavirus-2 (SARS CoV-2 or n-COV19), the cause of COVID-19. Protein J. 2020;39(3):198-216.
   Web of Science ®Google Scholar
• El-Nabi SH, Elhiti M, El-Sheekh M. A new approach for COVID-19 treatment by micro-RNA. Med Hypotheses. 2020;143:110203.
   PubMed Web of Science ®Google Scholar
• Martines RB, Ritter JM, Matkovic E, et al. Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States. Emerg Infect Dis. 2020;26:2005.
   PubMed Web of Science ®Google Scholar
• Benvenuto D, Angeletti S, Giovanetti M, et al. Evolutionary analysis of SARS-CoV-2: how mutation of non-structural protein 6 (NSP6) could affect viral autophagy. J Infect. 2020;81(1):24-27.
   Web of Science ®Google Scholar
• García LF. Immune response, inflammation, and the clinical spectrum of COVID-19. Front Immunol. 2020;11:1441.
   PubMed Web of Science ®Google Scholar
• Prasanna PL, Abilash V. Coronaviruses pathogenesis, comorbidities and multi-organ damage–A review. Life Sci. 2020;255:117839.
   PubMed Web of Science ®Google Scholar
• Demongeot J, Seligmann H. SARS-CoV-2 and miRNA-like inhibition power. Med Hypotheses. 2020;144:110245.
   PubMed Web of Science ®Google Scholar
• Satyam R, Bhardwaj T, Goel S, et al. miRNAs in SARS-CoV 2: A spoke in the wheel of pathogenesis. Current pharmaceutical design; 2020.
   Google Scholar
• Raman C, Ren C, Boas S, et al. TCR signaling strength dependent regulation of T cell proliferation, survival and Th differentiation by TGF-βR3 (betaglycn). Am Assoc Immnol. 2017;7:6.
   Google Scholar
• Tikhanovich I, Cox J, Weinman SA. Forkhead box class O transcription factors in liver function and disease. J Gastroenterol Hepatol. 2013;28:125–131.
   PubMed Web of Science ®Google Scholar
• Gamberi T, Magherini F, Modesti A, et al. Adiponectin signaling pathways in liver diseases. Biomedicines. 2018;6:52.
   PubMed Web of Science ®Google Scholar
• Samuel CE. ADARs: viruses and innate immunity. Adenosine deaminases acting on RNA (ADARs) and A-to-I editing. Springer; 2011. p. 163–195.
   Google Scholar
• Hayden M, West A, Ghosh S. NF-κ B and the immune response. Oncogene. 2006;25:6758–6780.
   PubMed Web of Science ®Google Scholar
• Gangemi S, Tonacci A AntagomiRs: A novel therapeutic strategy for challenging COVID-19 cytokine storm. Cytokine & growth factor reviews; 2020.
   Google Scholar
• Kumar S, Nyodu R, Maurya VK, et al. Host immune response and immunobiology of human SARS-CoV-2 infection. Coronavirus disease 2019 (COVID-19). Singapore: Springer; 2020. p. 43–53.
   Google Scholar
• Saini S, Saini A, Jyoti Thakur C, et al. Genome-wide computational prediction of miRNAs in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) revealed target genes involved in pulmonary vasculature and antiviral innate immunity. Mol Biol Res Commun. 2020;9:83–91.
   PubMed Web of Science ®Google Scholar
• Srivastava R, Daulatabad SV, Srivastava M, et al. Role of SARS-CoV-2 in altering the RNA-binding protein and miRNA-directed post-transcriptional regulatory networks in humans. Int J Mol Sci. 2020;21:7090.
   Web of Science ®Google Scholar
• Srivastava R, Daulatabad SV, Srivastava M, et al. SARS-CoV-2 contributes to altering the post-transcriptional regulatory networks across human tissues by sponging RNA binding proteins and micro-RNAs. BioRxiv. 2020.
   Google Scholar
• Bartoszewski R, Dabrowski M, Jakiela B, et al. SARS-CoV-2 may regulate cellular responses through depletion of specific host miRNAs. Am J Physiol Lung Cell Mol Physiol. 2020;319:L444–L55.
   PubMed Web of Science ®Google Scholar
• Nainu F, Shiratsuchi A, Nakanishi Y. Induction of apoptosis and subsequent phagocytosis of virus-infected cells as an antiviral mechanism. Front Immunol. 2017;8:1220.
   PubMed Web of Science ®Google Scholar
• Ivanisenko NV, Seyrek K, Kolchanov NA, et al. The role of death domain proteins in host response upon SARS-CoV-2 infection: modulation of programmed cell death and translational applications. Cell Death Discov. 2020;6:1–10.
   PubMed Web of Science ®Google Scholar
• Ramaiah MJ. mTOR inhibition and p53 activation, microRNAs: the possible therapy against pandemic COVID-19. Gene Rep. 2020;20:100765.
   PubMed Web of Science ®Google Scholar
• Makhdoumi P, Roohbakhsh A, Karimi G. MicroRNAs regulate mitochondrial apoptotic pathway in myocardial ischemia-reperfusion-injury. Biomed Pharmacother. 2016;84:1635–1644.
   PubMed Web of Science ®Google Scholar
• Omidkhoda N, Hayes AW, Reiter RJ, et al. The role of MicroRNAs on endoplasmic reticulum stress in myocardial ischemia and cardiac hypertrophy. Pharmacol Res. 2019;150:104516.
   PubMed Web of Science ®Google Scholar
• Hanna J, Hossain GS, Kocerha J. The potential for microRNA therapeutics and clinical research. Front Genet. 2019;10:478.
   PubMed Web of Science ®Google Scholar
• Chakraborty C, Sharma AR, Sharma G. Therapeutic advances of miRNAs: A preclinical and clinical update. J Adv Res. 2020;28:127–138.
   PubMed Web of Science ®Google Scholar
• Fulzele S, Sahay B, Yusufu I, et al. COVID-19 virulence in aged patients might be impacted by the host cellular microRNAs abundance/profile. Aging Dis. 2020;11:509.
   PubMed Web of Science ®Google Scholar
• Guterres A, de Azeredo Lima CH, Miranda RL, et al. What is the potential function of microRNAs as biomarkers and therapeutic targets in COVID-19? Infection. Gene Evolut. 2020;85:104417.
   PubMed Web of Science ®Google Scholar
• Mishra PK, Tandon R, Byrareddy SN. Diabetes and COVID-19 risk: an miRNA perspective. Am J Physiol Heart Circ Physiol. 2020;319:H604–H9.
   PubMed Web of Science ®Google Scholar
• Li C, Hu X, Li L, et al. Differential microRNA expression in the peripheral blood from human patients with COVID‐19. J Clin Lab Anal. 2020;34(10):e23590.
   PubMed Web of Science ®Google Scholar
• Baumann V, Winkler J. miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agents. Future Med Chem. 2014;6:1967–1984.
   PubMed Web of Science ®Google Scholar
• Fu Y, Chen J, Huang Z. Recent progress in microRNA-based delivery systems for the treatment of human disease. ExRNA. 2019;1:1–14.
   PubMedGoogle Scholar
• Zhou L-K, Zhou Z, Jiang X-M, et al. Absorbed plant MIR2911 in honeysuckle decoction inhibits SARS-CoV-2 replication and accelerates the negative conversion of infected patients. Cell Discov. 2020;6:1–4.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Zhou Y, Jiang X-M, et al. Decreased HD-MIR2911 absorption in human subjects with the SIDT1 polymorphism fails to inhibit SARS-CoV-2 replication. Cell Discov. 2020;6:1–4.
   PubMed Web of Science ®Google Scholar